This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.—In their thorough study, Dr Rosenberg and colleagues¹ did not find that calcium antagonists increased the risk of malignancy, apart from renal cell carcinoma. By looking at all prospective randomized studies in which calcium antagonists were compared with another drug or with a placebo, we recently have confirmed their findings.² However, the authors also reported an increased risk of renal cell carcinoma in patients taking a calcium antagonist and in those taking an angiotensin-converting enzyme inhibitor or a -blocker and suggest, therefore, that hypertension, in and of itself, may be a risk for renal cell carcinoma.

Although we cannot exclude this possibility, it seems more likely that this risk of renal cell carcinoma was due to concomitant diuretic use. No fewer than 9 case-control studies and 3 cohort studies suggest that long-term diuretic therapy confers a risk for renal cell carcinoma (other references available from author on . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antihypertensive therapy and the risk of malignancies
Grossman et al.
Eur Heart J 2001;22:1343-1352.
ABSTRACT